Returning to work after multimodal treatment in glioblastoma patients

Neurosurgical Focus
Daniele StarnoniJacques Guyotat

Abstract

OBJECTIVE Although multimodal treatment for glioblastoma (GBM) has resulted in longer survival, uncertainties exist regarding health-related quality of life and functional performance. Employment represents a useful functional end point and an indicator of social reintegration. The authors evaluated the rate of patients resuming their employment and the factors related to work capacity. METHODS The authors performed a retrospective study of working-age patients treated with surgery and radiochemotherapy between 2012 and 2015. Data were collected before and after surgery and at 6, 12, 18, and 24 months. Employment was categorized according to the French Socio-Professional Groups and analyzed regarding demographic and clinical data, performance status, socio-professional category, radiological features, type, and quality of resection. RESULTS A total of 125 patients, mean age 48.2 years, were identified. The mean follow-up was 20.7 months with a median survival of 22.9 months. Overall, 21 patients (18.3%) went back to work, most on a part-time basis (61.9%). Of the patients who were alive at 6, 12, 18, and 24 months after diagnosis, 8.7%, 13.8%, 15.3%, and 28.2%, respectively, were working. Patients going back to work were younge...Continue Reading

References

Apr 30, 1993·International Journal of Radiation Oncology, Biology, Physics·L KleinbergM G Malkin
Oct 1, 1996·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·A GregorS Love
Aug 17, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·A R Giovagnoli
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D OsobaM Prados
Oct 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M KleinN K Aaronson
Aug 27, 2002·Journal of Neurology·Jan J Heimans, Martin J B Taphoorn
Jan 9, 2003·The Lancet Oncology·Fabio Efficace, Andrew Bottomley
Jun 20, 2003·Journal of Neuro-oncology·Manuela SchmidingerChristine Marosi
Mar 4, 2005·Psycho-oncology·Deborah S MainJohn F Steiner
Feb 20, 2009·JAMA : the Journal of the American Medical Association·Angela G E M de BoerJos H A M Verbeek
Oct 15, 2010·Journal of Cancer Survivorship : Research and Practice·Michael FeuersteinXinhua Yu
Nov 3, 2011·Journal of Neuro-oncology·Derek R Johnson, Brian Patrick O'Neill
Mar 6, 2012·Neuro-Chirurgie·S ZouaouiUNKNOWN Association des neuro-oncologues d’expression française (ANOCEF)
Jan 29, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Nicolas R SmollOliver P Gautschi
Nov 12, 2013·Journal of Cancer Survivorship : Research and Practice·Cecelia GzellM Back
Feb 15, 2017·Journal of Cancer Survivorship : Research and Practice·L GatelyJ Philip

❮ Previous
Next ❯

Citations

Sep 23, 2020·Journal of Neuro-oncology·Christian SenftMarie-Thérèse Forster
Dec 20, 2019·Journal of Neuro-oncology·Akihito YoshidaToshihiko Wakabayashi
Nov 17, 2020·Frontiers in Human Neuroscience·Fabiola SilvaggiSilvia Schiavolin
Feb 23, 2021·Frontiers in Human Neuroscience·Silvia SchiavolinMatilde Leonardi

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.